A WORLD OF CARE
Biologic medicines have become the standard of care for many serious diseases like cancer, autoimmune disorders and diabetes.
WHAT ARE BIOSIMILARS
marvels of modern science
Biologics have revolutionized the treatment of many diseases. Biosimilar medicines offer physicians additional therapeutic options to essential, but often expensive, reference products.
Biologics are highly complex and often expensive therapies.
A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.
A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.
WHAT IS A BIOSIMILAR?
WHAT IS A BIOSIMILAR?
we reach people
The most advanced drugs are of no use if patients don’t have access to them. Biologics are a case in point.
Only 2% of the U.S. population uses biologics, but they account for 40% of prescription drug spending. Of the top 20 most costly drugs in the world, 12 of them are biologics, representing ~$100 billion of the ~$153 billion spent on these medicines; Mylan has 9 of these products on the market or in its global product pipeline.
NO MATTER WHERE
ITS WHAT WE DO
A COMMITMENT TO BIOSIMILARS
biosimilars add value
Every biosimilar we add to our portfolio provides more patients in more countries with the treatment they need. We are committed to continuing to invest in biosimillars.
A GROWING PORTFOLIO
experience that counts
Both reference products and biosimilar medicines are made under carefully controlled conditions, known as Good Manufacturing Practices (GMP), to ensure that they are consistently produced to the required quality.
Mylan has made medicines for nearly 60 years and has a long history of manufacturing complex products.
Of our nearly 50 manufacturing sites around the world, 10 focus on product technology development, including biosimilars and respiratory products. One of our state-of-the-art complex analytical laboratories is located in Morgantown, West Virginia and is helping us lead the way in biosimilar development.
CENTERS OF EXCELLENCE
we’re easy to access
© 2018 Mylan N.V. All rights reserved.
2. IMS data